# Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)

> **NCT02023879** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 233 (actual)

## Conditions studied

- Hypercholesterolemia

## Interventions

- **DRUG:** Alirocumab
- **DRUG:** Placebo (for Alirocumab)
- **DRUG:** Non-statin LMT
- **OTHER:** Diet Alone

## Key facts

- **NCT ID:** NCT02023879
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-16
- **Primary completion:** 2014-10-27
- **Final completion:** 2017-06-30
- **Target enrollment:** 233 (ACTUAL)
- **Last updated:** 2018-07-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02023879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02023879, "Phase III Study To Evaluate Alirocumab in Patients With Hypercholesterolemia Not Treated With a Statin (ODYSSEY CHOICE II)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02023879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*